BMT for Severe Autoimmune Diseases: An Idea Whose Time Has Come

ONCOLOGY

Volumn 11, Issue 7, 1997, Pages 1001-1017

  Burt, Richard K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANIMAL; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CHILD; DISEASE MODEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MULTIPLE SCLEROSIS; PATIENT SELECTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; CHILD; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOSUPPRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; PATIENT SELECTION;

EID: 0031180268     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Gatti RA, Meuwissen HJ, Allen HD, et al: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1:1366-1369, 1967.
2. McRae BL, Vanderlugt CL, Dal Canto MC, et al: Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182:75-86, 1995.
3. Forman SJ, Nocker P, Gallagtier M: Pattern of T cell reconstitution following allogeneic bone marrow transplantation for acute hematologic malignancy. Transplantation 34:96-98, 1982.
4. Olsen GA, Gockerman JP, Bast RC, et al: Altered immunologic reconstitution after standard dose chemotherapy or high dose chemotherapy with autologous bone marrow support. Transplantation 46:57-60, 1988.
5. Heyler BJ, Howie JB: Renal disease associated with positive lupus erythematosus tests in a cross bred strain of mice. Nature 197:197, 1963.
6. Putterman C, Naparstek Y: Murine models of spontaneous systemic lupus erythematocus, in Autoimmune Disease Models: A Guidebook, pp 217-243. San Diego, Academic Press, Inc., 1994.
7. Akizuki M, Reeves JP, Steinberk AD: Expression of autoimmunity by NZB/NZW marrow. Clin Immunol Immunopathol 10:247-250, 1978.
8. Jimenez SD, Christner P: Animal models of systemic sclerosis. Clin Dermatol 12:425-436, 1994.
9. Kasturi KN, Shibata S, Muryoi T, et al: Tight-skin mouse: An experimental model for scleroderma. Int Rev Immunol 11:253-271, 1994.
10. van de Water J, Boyd R, Wick G, et al: The immunologic and genetic basis of avian scleroderma, an inherited fibrotic disease of line 200 chickens. Int Rev Immunol 11:273-282, 1994
11. Rose NR: Avian models of autoimmune disease: Lessons from the birds. Poul Science 73:984-990, 1994.
12. Warren BF, Watkins PE: Animal models of inflammatory bowel disease. J Pathol 172:313-316, 1994.
13. Mendez JD, Ramos HG: Animal models in diabetes research. Arch Med Res 25(4):367-375, 1994.
14. Hanafusa T, Miyagawa J, Nakajima H, et al: The NOD mouse. Diabetes Res Clin Pract 24(suppl):S307-S311, 1994.
15. Cohen PL, Eisenberg RA: The lpr and gld genes in systemic autoimmunity Life and death in the Fas lane. Immunol Today 13(11):427-428, 1992.
16. Drappa J, Brot N, Elkon KB: The Fas protein is expressed at high levels on double positive thymocytes and activated mature T cells in normal but not MRL/lpr mice. Proc Natl Acad Sci USA 90:10340-10344, 1993.
17. Walker MA, Harley RA, Delustro FA, et al: Adoptive transfer of tight-skin fibrosis to +/+ recipients by tsk bone barrow and spleen cells. Proc Soc Exp Biol Med 192:196-200, 1989.
18. LaFace DM, Peck AB: Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes 38:894-901, 1989.
19. Hayashida K, Ochi T, Fujimoto M, et al: Bone marrow changes in adjuvant-induced and collagen-induced arthritis. Arthritis Rheum 35(2):241-245, 1992.
20. Durie FH, Fava RA, Noelle RJ: Collagen-induced arthritis as a model of rheumatoid arthritis Clin Immunol Immunopathol 73(1):11-18, 1994.
21. Patrick S, Lindstrom J, Autoimmune response to acetylcholine receptor. Science 180:871-872, 1973.
22. Vincent A: Experimental autoimmune myasthenia gravis, in Autoimmune Disease Models: A Guidebook, pp 83-106. San Diego, Academic Press, 1994
23. Brocke S, Gijbels K, Stemman L: Experimental autoimmune encephalomyelins in the mouse, in Autoimmune Disease Models: A Guide-book, pp 1-14. San Diego, Academic Press, Inc , 1994.
24. Steinman L, Schwartz G, Waldor M, et al: in EAE: A Good Model for MS, pp 393-397. San Diego, Academic Press, Inc., 1984.
25. Rosenberg N: Experimental models of inflammatory myopathies. Bailliere's Clinical Neurology 2(3) 693-703, 1993.
26. Remlinger J: Accidents paralytiques au cours du traitment antirabique. Ann Inst Pasteur 19:625-646, 1905.
27. Ikehara S, Good RA, Nakamura T, et al: Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 82:2483-2487, 1985.
28. Himeno K, Good RA: Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice. Proc Natl Acad Sci USA 85(7):2235-2239, 1988
29. Ikehara S, Yasumizu R, Inaba M, et al: Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 86:3306-3310, 1989.
30. Kamiya M, Sollen S, Yamane T, et al: Effective treatment of mice with type II collagen induced arthritis with lethal radiation and bone marrow transplantation. J Rheumatol 20:225-230, 1993.
31. Knaan-Schanzer S, Houben P, KinwelBohre EP, et al: Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant 8:333-338, 1991.
32. Pestronk A, Drachman DB, Teoh R, et al: Combined short-term immunotherapy cures experimental autoimmune myasthenia gravis. Ann Neurol 14:235-241, 1983.
33. Karussis DM, Vaurka-Karussis U, Lehmann D, et al: Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation J Clin Invest 765-772, 1993.
34. van Gelder M, Kinwel-Bohre EPM, van Bekkum DW: Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant 11:233-241, 1993.
35. van Gelder M, van Bekkum DW: Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 16:343-351, 1995.
36. b8.2T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J Neuroscience Res 41:526-531, 1995.
37. Lowenthal RM, Cohen ML, Atkinson K, et al: Apparent cure of rheumatoid arthritis by bone marrow transplatation. J Rheumatol 20(1):137-140, 1993.
38. McKendry RJR, Huebsch L, Leclair B: Progression of rheumatoid arthritis following bone marrow transplantation: A case report with 13 year followup. Arthritis Rheum 39:1246-1253, 1996.
39. Liu Yin JA, Jowitt SN: Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 9:31-33, 1992.
40. McAllister LD, Beatty PG, Rose J: Allogeneic bone marrow transplantation for chronic myelogenious leukemia in a patient with multiple sclerosis, case study Bone Marrow Transplant, 1997 (in press).
41. Salzman P, Tami J, Jackson C, et al: Clinical remission of myasthenia gravis after high dose chemotherapy and autologous transplantation with CD34+ stem cells (abstract). Blood 84(10; suppl 1):206a, 1994.
42. Fastenrath S, Dreger P, Schmitz N: Autologous unpurged bone marrow transplantation in a patient with lymphoma and SLE: Short-term recurrence of antinuclear antibodies. Arthritis Rheum 38(9):S303, 1995.
43. Euler HH, Marmont AM, Bacigalupo A, et al: Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 88(9):3621-3625, 1996.
44. Weinshenker BG: The natural history of multiple sclerosis. Multiple Sclerosis 13(1)119-146, 1995.
45. McFarland HG: Editorial: Twin studies and multiple sclerosis. Ann Neurol 32:722, 1992.
46. Kurtzke JF, Hyllested K, Heltberg A, et al: Multiple sclerosis in the Faroe Islands. Acra Neurol Scand 88:161-173, 1993.
47. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology (Cleveland) 33:1444-1452, 1983.
48. Sipe JC, Knobler RL, Braheny SL, et al: A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (Cleveland) 34:1368-1372, 1984.
49. Miller DH: Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 36(suppl):S91-S94, 1994.
50. Frank JA, Stone LA, Smith ME, et al: Serial contrast-enhaced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 36(suppl):SS6-S90, 1994.
51. Francis GS, Evans AC, Aronold DL: Neuroimaging in multiple sclerosis. Multiple Sclerosis 13(1):147-17, 1995.
52. Pincus T, Brooks RH, Callahan LF: Pre- diction of long-term morality in patients with rheumatoid arthritis according to simple questionaire and joint count measures Ann Intern Med 120:26-34, 1994.
53. Pincus T, Callahan LF: Rheumatology function tests: Grip strength, walking time, button test and questionnaires document and predict long-term morbidity and morality in rheumatiod arthritis. J Rheum 19(7):1051-1057, 1992.
54. Pincus T: Rheumatoid arthritis: A medical emergency? Scand J Rheum 23(suppl 100):21-30, 1994.
55. Jacobsson LT, Knowler WC, Pillemer S, et al: A cross-sectional and longitudinal comparison of the Rome criteria for active rheumatoid arthritis (equivalent to the American College of Rheumatology 1958 criteria) and the American College of Rheumatology 1987 criteria for rheumatoid arthritis. Arthritis Rheum 37(10):1479-1486, 1994.
56. Furst DE: Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Diagnostic Issues 20(2):309-319, 1994.
57. Corbett M, Dalton S, Young A, et al: Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheum 32:717-723, 1993.
58. Wolfe F, Mitchell DM, Sibley JT, et al: The morality of rheumatoid arthritis. Arthritis Rheum 37(4):481-494, 1994.
59. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, et al: Shortening of life span and causes of excess morality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheum 13:149-153, 1995.
60. Bendtsen P, Bjurulf P, Trell E, et al: Cross-sectional assessment and subgroup comparison of functional disability in patients with rheumatoid arthritis in a Swedish health-care district. Disabil Rehabil 17(2):94-99, 1995.
61. Pincus T, Callahan LF: The "side effects" of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol 32(suppl 1):28-37, 1993.
62. Pincus T, Summey JA, Soraci SA Jr., et al: Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum 26(11):1346-1353, 1983.
63. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271-1277, 1982.
64. Cheigh JS, Kim H, Stenzel KH, et al: Systemic lupus erythematosus in patients with end-stage renal disease: Long term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 16(3):189-195, 1990.
65. Seleznick MJ, Fries JF: Variables associated with decreased survival in Systemic lupus erythematosus. Semin Arthritis Rheum 21(2):73-80, 1991.
66. Gladman DD: Prognosis of systemic lupus erthematousus and factors that affect it. Rheumatology 4:681-687, 1992.
67. Choen MG, Li EK: Morality in systemic lupus erythematosus: Active disease is the most important factor. NZ J Med 22:5-8, 1992.
68. Churg J, Sobin LN: Glomerular diseases, in Renal Disease Classification and Atlas, vol 1. Tokyo, Igaku-shoin, 1982.
69. Kashgarian M: New approaches to clinical pathologic correlation in lupus nephritis. Am J Kidney Dis 2:164-169, 1982.
70. Austin, HA III, Muenz LR, Joyce KM, et al: Prognostic factors in lupus nephritis: Contribution of renal histology data. Am J Med 75:382-391, 1983.
71. McLaughlin J, Gladman DD, Urowitz MB, et al: Kidney biopsy in systemic lupus erythematosus. Arthritis Rheum 34(10):1268-1272, 1991.
72. Bombardier C, Gladman DD, Urowitz MB, et al: Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 35(6):630-640, 1992.
73. Abu-Shakra M, Urowitz MB, Gladman DD, et al: Morality studies in systeic lupus erythematosus, results from a single center: II. Predictor variables for mortality. J Rheum 22(7):1265-1270, 1995.
74. Cohen MG, Li EK: Morality in systemic lupus erythematosus: Active disease is the most important factor. Aust NZ J Med 22:5-8, 1992.
75. Gladman DD: Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 5:587-595, 1993.
76. Gulko PS, Reveille JD, Koopman WJ, et al: Anticardiolipin antibodies in systemic lupus erythematosus: Clinical correlates, HLA associations, and impact on survival. J Rheum 20(10):1684-1693, 1993.
77. Drenkard C, Villa AR, Alarcon-Segovia D, et al: Influence of the antiphosphohpid syndrome in the survival of patients with systemic lupus erythematosus. J Rheum 21(6):1067-1072, 1994.
78. Alarcon-Segovia D, Deleze M, Oria CV, et al: Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine 68(6):353-365, 1989.
79. Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheum 32:568-573, 1993.
80. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al: Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 118:602-609, 1993.
81. Langevitz LP, Alderdice CA, Aubrey M, et al: Morality in systemic sclerosis (scleroderma). J Med 82(298):139-148, 1992.
82. Altman RD, Medsger TA, Bloch DA, et al: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34(4):403-413, 1991
83. Drachman DB: Myasthenia gravis. N Engl J Med 330(25):1797-1810, 1994.
84. Sanders DB, Scoppetta C. The treatment of patients with myastenia gravis Neurol Clin North Am 12(2):343-368, 1994.
85. Somnier FE, Keiding N, Paulson OB: Epidemiology of myastenia gravis in Denmark. Arch Neurol 48:733-739, 1991.
86. Probert CSJ, Jayanthi V, Wicks ACB, et al: Mortality from Crohn's disease in Leicestershire, 1972-1989: An epidemiological community based study. Gut 33:1226-1228, 1992.
87. Mendelsolin RR, Korelitz BI, Gleim GW, Death from Crohn's disease and lessons from a personal experience. J Clin Gastroenterol 20(1):22-26, 1995.
88. Love LA, Lcff RL, Fraser DD, et al: A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoanitbodies define useful homogeneous patient groups. Medicine 70:360, 1991.